vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and MOVADO GROUP INC (MOV). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $186.1M, roughly 1.3× MOVADO GROUP INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 5.1%, a 6.0% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 1.9%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $11.6M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 2.9%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Movado is a luxury American watch brand originally founded in 1881 in Switzerland. Movado means "movement" in Esperanto. The watches are known for their signature metallic dot at 12 o'clock and minimalist style; the company is best known for its Museum Watch.
ANIP vs MOV — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $186.1M |
| Net Profit | $27.5M | $9.6M |
| Gross Margin | — | 54.3% |
| Operating Margin | 14.1% | 6.3% |
| Net Margin | 11.1% | 5.1% |
| Revenue YoY | 29.6% | 1.9% |
| Net Profit YoY | 367.5% | 89.8% |
| EPS (diluted) | $1.14 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $186.1M | ||
| Q3 25 | $227.8M | $161.8M | ||
| Q2 25 | $211.4M | $131.8M | ||
| Q1 25 | $197.1M | $181.5M | ||
| Q4 24 | $190.6M | $180.5M | ||
| Q3 24 | $148.3M | $157.0M | ||
| Q2 24 | $138.0M | $134.4M | ||
| Q1 24 | $137.4M | $175.8M |
| Q4 25 | $27.5M | $9.6M | ||
| Q3 25 | $26.6M | $3.0M | ||
| Q2 25 | $8.5M | $1.4M | ||
| Q1 25 | $15.7M | $8.1M | ||
| Q4 24 | $-10.3M | $4.8M | ||
| Q3 24 | $-24.2M | $3.5M | ||
| Q2 24 | $-2.3M | $2.0M | ||
| Q1 24 | $18.2M | $9.8M |
| Q4 25 | — | 54.3% | ||
| Q3 25 | — | 54.1% | ||
| Q2 25 | — | 54.1% | ||
| Q1 25 | — | 54.2% | ||
| Q4 24 | — | 53.5% | ||
| Q3 24 | — | 54.3% | ||
| Q2 24 | — | 54.3% | ||
| Q1 24 | — | 53.5% |
| Q4 25 | 14.1% | 6.3% | ||
| Q3 25 | 15.9% | 2.5% | ||
| Q2 25 | 6.6% | 0.2% | ||
| Q1 25 | 13.3% | 5.1% | ||
| Q4 24 | -2.3% | 3.3% | ||
| Q3 24 | -13.8% | 1.7% | ||
| Q2 24 | 3.7% | 1.6% | ||
| Q1 24 | 14.8% | 6.1% |
| Q4 25 | 11.1% | 5.1% | ||
| Q3 25 | 11.7% | 1.8% | ||
| Q2 25 | 4.0% | 1.1% | ||
| Q1 25 | 8.0% | 4.4% | ||
| Q4 24 | -5.4% | 2.7% | ||
| Q3 24 | -16.3% | 2.2% | ||
| Q2 24 | -1.7% | 1.5% | ||
| Q1 24 | 13.2% | 5.6% |
| Q4 25 | $1.14 | $0.42 | ||
| Q3 25 | $1.13 | $0.13 | ||
| Q2 25 | $0.36 | $0.06 | ||
| Q1 25 | $0.69 | $0.36 | ||
| Q4 24 | $-0.45 | $0.21 | ||
| Q3 24 | $-1.27 | $0.15 | ||
| Q2 24 | $-0.14 | $0.09 | ||
| Q1 24 | $0.82 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $183.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $497.5M |
| Total Assets | $1.4B | $751.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $183.9M | ||
| Q3 25 | $262.6M | $180.5M | ||
| Q2 25 | $217.8M | $203.1M | ||
| Q1 25 | $149.8M | $208.5M | ||
| Q4 24 | $144.9M | $181.5M | ||
| Q3 24 | $145.0M | $198.3M | ||
| Q2 24 | $240.1M | $225.4M | ||
| Q1 24 | $228.6M | $262.1M |
| Q4 25 | $540.7M | $497.5M | ||
| Q3 25 | $505.8M | $489.9M | ||
| Q2 25 | $436.8M | $493.2M | ||
| Q1 25 | $418.6M | $481.3M | ||
| Q4 24 | $403.7M | $491.3M | ||
| Q3 24 | $405.9M | $492.0M | ||
| Q2 24 | $455.8M | $489.6M | ||
| Q1 24 | $452.0M | $505.9M |
| Q4 25 | $1.4B | $751.9M | ||
| Q3 25 | $1.4B | $748.7M | ||
| Q2 25 | $1.3B | $747.2M | ||
| Q1 25 | $1.3B | $729.2M | ||
| Q4 24 | $1.3B | $747.2M | ||
| Q3 24 | $1.3B | $742.5M | ||
| Q2 24 | $920.8M | $736.0M | ||
| Q1 24 | $914.5M | $756.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $12.3M |
| Free Cash FlowOCF − Capex | $29.1M | $11.6M |
| FCF MarginFCF / Revenue | 11.8% | 6.2% |
| Capex IntensityCapex / Revenue | 0.5% | 0.4% |
| Cash ConversionOCF / Net Profit | 1.10× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $35.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $12.3M | ||
| Q3 25 | $44.1M | $-3.8M | ||
| Q2 25 | $75.8M | $-7.2M | ||
| Q1 25 | $35.0M | $39.1M | ||
| Q4 24 | $15.9M | $-4.7M | ||
| Q3 24 | $12.5M | $-17.8M | ||
| Q2 24 | $17.4M | $-18.1M | ||
| Q1 24 | $18.3M | $69.4M |
| Q4 25 | $29.1M | $11.6M | ||
| Q3 25 | $38.0M | $-5.1M | ||
| Q2 25 | $71.8M | $-8.7M | ||
| Q1 25 | $32.5M | $37.5M | ||
| Q4 24 | $13.5M | $-7.2M | ||
| Q3 24 | $7.7M | $-20.1M | ||
| Q2 24 | $13.0M | $-19.7M | ||
| Q1 24 | $13.7M | $67.8M |
| Q4 25 | 11.8% | 6.2% | ||
| Q3 25 | 16.7% | -3.1% | ||
| Q2 25 | 34.0% | -6.6% | ||
| Q1 25 | 16.5% | 20.7% | ||
| Q4 24 | 7.1% | -4.0% | ||
| Q3 24 | 5.2% | -12.8% | ||
| Q2 24 | 9.4% | -14.7% | ||
| Q1 24 | 10.0% | 38.6% |
| Q4 25 | 0.5% | 0.4% | ||
| Q3 25 | 2.7% | 0.8% | ||
| Q2 25 | 1.9% | 1.2% | ||
| Q1 25 | 1.3% | 0.9% | ||
| Q4 24 | 1.3% | 1.4% | ||
| Q3 24 | 3.2% | 1.5% | ||
| Q2 24 | 3.2% | 1.2% | ||
| Q1 24 | 3.3% | 0.9% |
| Q4 25 | 1.10× | 1.28× | ||
| Q3 25 | 1.66× | -1.27× | ||
| Q2 25 | 8.87× | -5.08× | ||
| Q1 25 | 2.23× | 4.86× | ||
| Q4 24 | — | -0.98× | ||
| Q3 24 | — | -5.14× | ||
| Q2 24 | — | -8.97× | ||
| Q1 24 | 1.00× | 7.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
MOV
| Other | $81.4M | 44% |
| Owned Brands Category | $46.0M | 25% |
| Sales Channel Directly To Consumer | $35.3M | 19% |
| Company Stores | $23.4M | 13% |
